Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 7Carcinoma, Merkel Cell 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Recurrence 3Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Cancer Resectable 1Non-Muscle Invasive Bladder Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Microsatellite Instability 1

Interventions

radium Ra 223 dichloride 2enzalutamide 2darolutamide 1avelumab 1abiraterone 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metastatic Castration-resistant Prostate Cancer × avelumab × Clear all
NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Tulane University

Phase 2 Terminated
8 enrolled 7 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡